Markers of Bone and Cartilage Turnover

被引:13
作者
Woitge, Henning W. [1 ]
Seibel, Markus J. [2 ]
机构
[1] ANZAC Res Inst, Bone Res Program, Sydney, NSW, Australia
[2] ANZAC Res Inst, Sydney, NSW 2139, Australia
关键词
bone; cartilage; metabolism; markers; osteoporosis; arthritis; OLIGOMERIC MATRIX PROTEIN; RESISTANT ACID-PHOSPHATASE; VERTEBRAL FRACTURE RISK; C-TERMINAL TELOPEPTIDE; II COLLAGEN; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; ALKALINE-PHOSPHATASE; JOINT FLUID; PROTEOGLYCAN FRAGMENTS;
D O I
10.1055/s-0043-106438
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past few decades, scientists have been trying to identify tissue-specific markers that would help to better understand the pathogenesis of bone and cartilage diseases and could be used clinically for the screening, diagnosis and followup of bone or joint diseases. Historically, only a few components known to be involved in bone, mineral or cartilage turnover were available for this purpose (e.g., urine hydroxyproline, serum and urine calcium and phosphate levels). However, since most if not all of these substances have wider biological functions beyond bone, mineral and cartilage metabolism, their clinical value as tissue-specific markers was limited. Hence, there was a need to identify more specific indices of bone and cartilage metabolism. Since the 1980s, a number of collagenous and non-collagenous breakdown products as well as cell-specific enzymes have been discovered and developed into markers of musculoskeletal tissue metabolism. This review describes their chemical and biological function, available analytical methods and possible clinical applications.
引用
收藏
页码:454 / 469
页数:16
相关论文
共 161 条
[101]   The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases [J].
Poole, AR ;
Ionescu, M ;
Fitzcharles, MA ;
Billinghurst, RC .
JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 294 (1-2) :145-153
[102]   Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments [J].
Pratta, M. A. ;
Su, J. L. ;
Leesnitzer, M. A. ;
Struglics, A. ;
Larsson, S. ;
Lohmander, L. S. ;
Kumar, S. .
OSTEOARTHRITIS AND CARTILAGE, 2006, 14 (07) :702-713
[103]   Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma [J].
Qian, Jianfei ;
Xie, Jin ;
Hong, Sungyoul ;
Yang, Jing ;
Zhang, Liang ;
Han, Xiaohong ;
Wang, Michael ;
Zhan, Fenghuang ;
Shaughnessy, John D., Jr. ;
Epstein, Joshua ;
Kwak, Larry W. ;
Yi, Qing .
BLOOD, 2007, 110 (05) :1587-1594
[104]  
Ratcliffe A, 1991, TRANS ORTH SOC, V16, P228
[105]   Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis [J].
Reginster, Jean-Yves .
DRUGS, 2011, 71 (01) :65-78
[106]   Short-term and long-term effects of osteoporosis therapies [J].
Reid, Ian R. .
NATURE REVIEWS ENDOCRINOLOGY, 2015, 11 (07) :418-428
[107]   Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease [J].
Reid, IR ;
Miller, P ;
Lyles, K ;
Fraser, W ;
Brown, JP ;
Saidi, Y ;
Mesenbrink, P ;
Su, GQ ;
Pak, J ;
Zelenakas, K ;
Luchi, M ;
Richardson, P ;
Hosking, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (09) :898-908
[108]   A new marker for osteoarthritis - Cross-sectional and longitudinal approach [J].
Reijman, M ;
Hazes, JMW ;
Bierma-Zeinstra, SMA ;
Koes, BW ;
Christgau, S ;
Christiansen, C ;
Uitterlinden, AG ;
Pols, HAP .
ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2471-2478
[109]   Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy [J].
Riggs, BL ;
Melton, LJ ;
OFallon, WM .
BONE, 1996, 18 (03) :S197-S201
[110]  
Risteli J, 1991, J BONE MINER RES S1, V6, pS251